Drugs / Invikafusp alfa
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06827613 | Mar 2025 → Jan 2027 expected | hormone receptor-positive breast cancer, triple-negative breast carcinoma | Marengo Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05592626 | Jan 2023 → Oct 2026 expected | Epstein-Barr virus infection, carcinoma, human papilloma virus infection, lung neoplasm +2 | Marengo Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Invikafusp alfa | “Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule” NCT06827613 ↗ |
| Known as | STAR0602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05592626 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068126 ↗ |
| Route | Intravenous | “intravenous infusion” NCT05592626 ↗ |